# Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Canonical: https://abierto.us/opportunities/ht940226q9103

- Solicitation number: HT9402-26-Q-9103
- Notice type: Solicitation
- Status: Closed. Deadline was January 5, 2026 at 1:00 PM EST
- Department: Department of Defense
- Agency: Defense Health Agency (Dha)
- Contracting office: Defense Health Agency (HT9402)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: San Antonio, Texas
- County: Bexar County (FIPS 48029). https://abierto.us/counties/bexar-county-tx-48029
- City: San Antonio. https://abierto.us/cities/san-antonio-tx-4865000
- First posted: December 11, 2025
- Last posted: December 17, 2025
- SAM.gov: https://sam.gov/workspace/contract/opp/59668aba0f06468b9b087d55646270ec/view

## Description

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.

The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).

Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

**P&T COMMITTEE MEETING:** The following February 2026 newly approved drugs will be reviewed: a. Hyrnuo - Lung Cancer - HER2+ b. Javadin - Antihypertensive Agents - N/A c. Komzifti - Leukemia and Lymphoma Agents - Acute Myelogenous Leukemia d. Lasix ONYU - Diuretics - N/A e. Redemplo - Antilipidemics-2 - N/A f. Starjemza - Targeted Immunomodulatory Biologics - Interleukin 23 The RFQ, including UF BPA and UF ADP appendices are attached here in.

The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9103. Pre-quotation teleconference is on December 17, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

## Publications

- December 11, 2025: Solicitation, due January 5, 2026 at 1:00 PM EST. Notice 7f828f4d50e040c5bcbcc894c50354fd. https://sam.gov/workspace/contract/opp/7f828f4d50e040c5bcbcc894c50354fd/view
- December 17, 2025: Solicitation, due January 5, 2026 at 1:00 PM EST. Notice 59668aba0f06468b9b087d55646270ec. https://sam.gov/workspace/contract/opp/59668aba0f06468b9b087d55646270ec/view

## Points of contact

- Tracy Banks, tracy.e.banks2.civ@health.mil
- Julia Trang, julia.n.trang.civ@health.mil

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/ht940226q9103.